Literature DB >> 18647744

High prevalence in cystic fibrosis patients of multiresistant hospital-acquired methicillin-resistant Staphylococcus aureus ST228-SCCmecI capable of biofilm formation.

Auxiliadora Molina1, Rosa Del Campo, Luis Máiz, María-Isabel Morosini, Adelaida Lamas, Fernando Baquero, Rafael Cantón.   

Abstract

OBJECTIVES: Although methicillin-resistant Staphylococcus aureus (MRSA) is increasingly recognized in cystic fibrosis (CF) patients, it has not been sufficiently studied in large series. We analysed all MRSA isolates recovered from respiratory secretions of patients attending our CF unit (1994-2006).
METHODS: Antibiotic susceptibilities were determined using both planktonic and sessile bacteria as inocula. Genetic relationships were determined by PFGE and multilocus sequence typing (MLST). SCCmec type and the presence of the pvl gene were also investigated.
RESULTS: A total of 93 MRSA isolates (1-20 isolates per patient) were recovered from 18 of 77 CF patients with positive staphylococcal culture. Mean prevalence (4.4%) increased (P < 0.001) over time. All isolates were susceptible to linezolid, quinupristin/dalfopristin and co-trimoxazole but presented high resistance rates to amikacin (90%), gentamicin (85%), levofloxacin (81%) and erythromycin (69%). Except for macrolides and gentamicin, isolates were less susceptible growing in biofilms than in planktonic cultures. Fifteen different PFGE patterns were found, one of them consistently recovered for 6 years in the same patient. Identical clones were detected in several unrelated patients. MLST demonstrated that the international ST228 was the most frequent (67%) clone. The pvl gene was negative in all isolates and the SCCmec corresponded to types I (97%) and IV (3%). Strong mutators were not detected, but a considerable number were considered weak mutators.
CONCLUSIONS: Distinct microbiological and molecular features were detected among CF-MRSA isolates, probably due to adaptation to specific conditions in CF patients. Prevalence of MRSA increased among these patients, most of them colonized with a multiresistant biofilm-forming clone belonging to ST228-SSCmecI, suggesting cross-transmission or a common source.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18647744     DOI: 10.1093/jac/dkn302

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  19 in total

1.  Genetic diversity of methicillin-resistant Staphylococcus aureus in a tertiary hospital in The Netherlands between 2002 and 2006.

Authors:  E Nulens; E E Stobberingh; E Smeets; H van Dessel; M A Welling; S Sebastian; F H van Tiel; P S Beisser; R H Deurenberg
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-01-08       Impact factor: 3.267

Review 2.  Pharmacokinetic and Pharmacodynamic Optimization of Antibiotic Therapy in Cystic Fibrosis Patients: Current Evidences, Gaps in Knowledge and Future Directions.

Authors:  Charlotte Roy; Manon Launay; Sophie Magréault; Isabelle Sermet-Gaudelus; Vincent Jullien
Journal:  Clin Pharmacokinet       Date:  2021-01-24       Impact factor: 6.447

3.  Impact of a short period of pre-enrichment on detection and bacterial loads of methicillin-resistant Staphylococcus aureus from screening specimens.

Authors:  L Van Heirstraeten; J Cortiñas Abrahantes; C Lammens; A Lee; S Harbarth; G Molenberghs; M Aerts; H Goossens; S Malhotra-Kumar
Journal:  J Clin Microbiol       Date:  2009-08-12       Impact factor: 5.948

Review 4.  Pharmacological issues of linezolid: an updated critical review.

Authors:  Antonello Di Paolo; Paolo Malacarne; Emanuele Guidotti; Romano Danesi; Mario Del Tacca
Journal:  Clin Pharmacokinet       Date:  2010-07       Impact factor: 6.447

5.  In vivo attenuation and genetic evolution of a ST247-SCCmecI MRSA clone after 13 years of pathogenic bronchopulmonary colonization in a patient with cystic fibrosis: implications of the innate immune response.

Authors:  E López-Collazo; T Jurado; J de Dios Caballero; M Pérez-Vázquez; A Vindel; E Hernández-Jiménez; J Tamames; C Cubillos-Zapata; M Manrique; R Tobes; L Máiz; R Cantón; F Baquero; R Del Campo
Journal:  Mucosal Immunol       Date:  2014-08-13       Impact factor: 7.313

Review 6.  Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic.

Authors:  Michael Z David; Robert S Daum
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

7.  Emergence of linezolid-resistant Staphylococcus aureus after prolonged treatment of cystic fibrosis patients in Cleveland, Ohio.

Authors:  Andrea Endimiani; Martha Blackford; Elliot C Dasenbrook; Michael D Reed; Saralee Bajaksouszian; Andrea M Hujer; Susan D Rudin; Kristine M Hujer; Vincent Perreten; Louis B Rice; Michael R Jacobs; Michael W Konstan; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2011-01-24       Impact factor: 5.191

Review 8.  Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients.

Authors:  Axel Dalhoff
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

9.  Molecular characterization of resistance to Rifampicin in an emerging hospital-associated Methicillin-resistant Staphylococcus aureus clone ST228, Spain.

Authors:  Virginie Mick; M Angeles Domínguez; Fe Tubau; Josefina Liñares; Miquel Pujol; Rogelio Martín
Journal:  BMC Microbiol       Date:  2010-03-04       Impact factor: 3.605

10.  Longitudinal survey of Staphylococcus aureus in cystic fibrosis patients using a multiple-locus variable-number of tandem-repeats analysis method.

Authors:  Hoang Vu-Thien; Katia Hormigos; Gaëlle Corbineau; Brigitte Fauroux; Harriet Corvol; Didier Moissenet; Gilles Vergnaud; Christine Pourcel
Journal:  BMC Microbiol       Date:  2010-01-27       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.